Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, et al. CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2024;8:3562–75.
Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T-cell therapy. Nat Rev Clin Oncol. 2020;17:147–67.
Harrison AJ, Du X, von Scheidt B, Kershaw MH, Slaney CY. Enhancing costimulation of CAR T cells to improve treatment outcomes in solid cancers. Immunother Adv. 2021;1:ltab 016.
Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388–98.
Katsarou A, Sjostrand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G, et al. Combining a CAR and a chimeric costimulatory receptor enhances T-cell sensitivity to low antigen density and promotes persistence. Sci Transl Med. 2021;13:eabh1962.
Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012;32:1059–70.
Muliaditan T, Halim L, Whilding LM, Draper B, Achkova DY, Kausar F, et al. Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors. Cell Rep Med. 2021;2:100457.
Hernández-López P, van Diest E, Brazda P, Heijhuurs S, Meringa A, Hoorens van Heyningen L, et al. Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells. Nat Immunol. 2024;25:88–101.
Chen C, Gu YM, Zhang F, Zhang ZC, Zhang YT, He YD, et al. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer. Oncoimmunology. 2021;10:1901434.
Zhao Z, Sadelain M. CAR T-cell design: approaching the elusive AND-gate. Cell Res. 2023;33:739–40.
Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q, et al. CD19-specific CAR T cells that express a PD-1/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma. Clin Cancer Res. 2021;27:473–84.
Zhang C, Liu H. Advancements and future directions of dual-target chimeric antigen receptor T-cell therapy in preclinical and clinical studies. J Immunol Res. 2025;2025:5845167.
Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B-cell malignancies: a phase 1 trial. Nat Med. 2021;27:1419–31.
Otano I, Azpilikueta A, Glez-Vaz J, Alvarez M, Medina-Echeverz J, Cortés-Domínguez I, et al. CD137 (4-1BB) costimulation of CD8(+) T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. Nat Commun. 2021;12:7296.
Hernandez-Lopez P, van Diest E, Brazda P, Heijhuurs S, Meringa A, Hoorens van Heyningen L, et al. Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells. Nat Immunol. 2024;25:88–101.
Harly C, Guillaume Y, Nedellec S, Peigné CM, Mönkkönen H, Mönkkönen J, et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood. 2012;120:2269–79.
Liang F, Zhang C, Guo H, Gao SH, Yang FY, Zhou GB, et al. Comprehensive analysis of BTN3A1 in cancers: mining of omics data and validation in patient samples and cellular models. FEBS Open Bio. 2021;11:2586–99.
Beringer DX, Straetemans T, Minguet S, Riillo C, Lynch L, Sebestyen Z, et al. Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapy. Nat Rev Cancer. 2025;25:590–612.
Willcox CR, Salim M, Begley CR, Karunakaran MM, Easton EJ, von Klopotek C, et al. Phosphoantigen sensing combines TCR-dependent recognition of the BTN3A IgV domain and germline interaction with BTN2A1. Cell Rep. 2023;42:112321.
Rigau M, Ostrouska S, Fulford TS, Johnson DN, Woods K, Ruan Z, et al. Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells. Science. 2020;367:eaay5516.
Payne KK, Mine JA, Biswas S, Chaurio RA, Perales-Puchalt A, Anadon CM, et al. BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells. Science. 2020;369:942–9.
Kone AS, Ait Ssi S, Sahraoui S, Badou A. BTN3A: a promising immune checkpoint for cancer prognosis and treatment. Int J Mol Sci. 2022;23:13424.
Herrmann T, Karunakaran MM. Phosphoantigen recognition by Vgamma9Vdelta2 T cells. Eur J Immunol. 2024;54:e2451068.
Weiss HM, Pfaar U, Schweitzer A, Wiegand H, Skerjanec A, Schran H. Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos. 2008;36:2043–9.
Li X, Valdes SA, Alzhrani RF, Hufnagel S, Hursting SD, Cui Z. Zoledronic acid-containing nanoparticles with minimum premature release show enhanced activity against extraskeletal tumor. ACS Appl Mater Interfaces. 2019;11:7311–9.
Grunder C, van Dorp S, Hol S, Drent E, Straetemans T, Heijhuurs S, et al. gamma9 and delta2CDR3 domains regulate functional avidity of T cells harboring gamma9delta2TCRs. Blood. 2012;120:5153–62.
Le Floch AC, Imbert C, Boucherit N, Gorvel L, Fattori S, Orlanducci F, et al. Targeting BTN2A1 enhances Vgamma9Vdelta2 T-cell effector functions and triggers tumor cell pyroptosis. Cancer Immunol Res. 2024;12:1677–90.
Palakodeti A, Sandstrom A, Sundaresan L, Harly C, Nedellec S, Olive D, et al. The molecular basis for modulation of human Vgamma9Vdelta2 T-cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies. J Biol Chem. 2012;287:32780–90.
Fulford TS, Soliman C, Castle RG, Rigau M, Ruan Z, Dolezal O, et al. Vgamma9Vdelta2 T cells recognize butyrophilin 2A1 and 3A1 heteromers. Nat Immunol. 2024;25:1355–66.
Fulford TS, Soliman C, Castle RG, Rigau M, Ruan Z, Dolezal O, et al. Vγ9Vδ2 T cells recognize butyrophilin 2A1 and 3A1 heteromers. Nat Immunol. 2024;25:1355–66.
Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood. 2007;109:2331–8.
Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4-1BB costimulation ameliorates T-cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581–90.
Roussel M, Le KS, Granier C, Llamas Gutierrez F, Foucher E, Le Gallou S, et al. Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade. Blood Adv. 2021;5:1816–29.
Yang ZZ, Kim HJ, Villasboas JC, Chen YP, Price-Troska T, Jalali S, et al. Expression of LAG-3 defines exhaustion of intratumoral PD-1(+) T cells and correlates with poor outcome in follicular lymphoma. Oncotarget. 2017;8:61425–39.
Clark ES, Brown B, Whigham AS, Kochaishvili A, Yarbrough WG, Weaver AM. Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in the 11q13 amplicon. Oncogene. 2009;28:431–44.
Philipson BI, O’Connor RS, May MJ, June CH, Albelda SM, Milone MC. 4-1BB costimulation promotes CAR T-cell survival through noncanonical NF-κB signaling. Sci Signal. 2020;13:eaay8248.
Correction: Leveraging T-cell costimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer. J Immunother Cancer. 2025;13:e010140.
Kawalekar OU, O’Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44:712.
Minguet S, Maus MV, Schamel WW. From TCR fundamental research to innovative chimeric antigen receptor design. Nat Rev Immunol. 2025;25:212–24.
Tang L, Pan S, Wei X, Xu X, Wei Q. Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development. Mol Ther. 2023;31:3146–62.
Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016;76:1578–90.
Prosser ME, Brown CE, Shami AF, Forman SJ, Jensen MC. Tumor PD-L1 costimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol Immunol. 2012;51:263–72.
Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B-cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13:30.
Leung I, Templeton ML, Lo Y, Rajan A, Stull SM, Garrison SM, et al. Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function. Blood Adv. 2023;7:2718–30.
Vyborova A, Beringer DX, Fasci D, Karaiskaki F, van Diest E, Kramer L, et al. gamma9delta2T cell diversity and the receptor interface with tumor cells. J Clin Invest. 2020;130:4637–51.
Karunakaran MM, Subramanian H, Jin Y, Mohammed F, Kimmel B, Juraske C, et al. A distinct topology of BTN3A IgV and B30.2 domains controlled by juxtamembrane regions favors optimal human gammadelta T-cell phosphoantigen sensing. Nat Commun. 2023;14:7617.
Zhang M, Wang Y, Cai N, Qu Y, Ma X, Xue J, et al. Structures of butyrophilin multimers reveal a plier-like mechanism for Vγ9Vδ2 T-cell receptor activation. Immunity. 2025;58:1660–9.e7.
Zhu Y, Gao W, Zheng J, Bai Y, Tian X, Huang T, et al. Phosphoantigen-induced inside-out stabilization of butyrophilin receptor complexes drives dimerization-dependent γδ TCR activation. Immunity. 2025;58:1646–59.e5.
Fleischer LC, Becker SA, Ryan RE, Fedanov A, Doering CB, Spencer HT. Nonsignaling chimeric antigen receptors enhance antigen-directed killing by gammadelta T cells in contrast to alphabeta T cells. Mol Ther Oncolytics. 2020;18:149–60.
Qu QX, Zhu XY, Du WW, Wang HB, Shen Y, Zhu YB, et al. 4-1BB agonism combined with PD-L1 blockade increases the number of tissue-resident CD8+ T cells and facilitates tumor abrogation. Front Immunol. 2020;11:577.
Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One. 2011;6:e19499.
Claus C, Ferrara-Koller C, Klein C. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy. MAbs. 2023;15:2167189.
Hu H, Tang L, Zhao Y, Cheng J, Huang M, You Y, et al. Single-cell analysis of the survival mechanisms of fratricidal CAR-T targeting of T cell malignancies. Mol Ther Nucleic Acids. 2024;35:102225.
Gower M, Tikhonova AN. Avoiding fratricide: a T-ALL order. Blood. 2022;140:3–4.
Vazaios K, Hernández López P, Aarts-Riemens T, Daudeij A, Kemp V, Hoeben RC, et al. Unusual partners: γδ-TCR-based T-cell therapy in combination with oncolytic virus treatment for diffuse midline gliomas. Int J Mol Sci. 2025;26:2167.
Vyborova A, Beringer DX, Fasci D, Karaiskaki F, van Diest E, Kramer L, et al. γ9δ2T cell diversity and the receptor interface with tumor cells. J Clin Invest. 2020;130:4637–51.
van Diest E, Hernández López P, Meringa AD, Vyborova A, Karaiskaki F, Heijhuurs S, et al. Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds. J Immunother Cancer. 2021;9:e003850.
Ramos AR, Ghosh S, Dedobbeleer M, Robe PA, Rogister B, Erneux C. Lipid phosphatases SKIP and SHIP2 regulate fibronectin-dependent cell migration in glioblastoma. FEBS J. 2019;286:1120–35.
Cleven A, Meringa AD, Brazda P, Fasci D, Koorman T, Aarts T, et al. Sensitivity to Vγ9Vδ2TCR T cells is imprinted after single mutations during early oncogenesis. bioRxiv. 2024. https://www.biorxiv.org/content/10.1101/2024.11.19.624272v1.full.
Kierkels GJJ, van Diest E, Hernández-López P, Scheper W, de Bruin ACM, Frijlink E, et al. Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells. Mol Ther Methods Clin Dev. 2021;22:388–400.
Marcu-Malina V, Heijhuurs S, van Buuren M, Hartkamp L, Strand S, Sebestyen Z, et al. Redirecting alphabeta T cells against cancer cells by transfer of a broadly tumor-reactive gammadeltaT-cell receptor. Blood. 2011;118:50–9.